AURORA, Sheena,JOHNSON, Kirk Willis,KREGE, John Henry
申请号：
SG11202001387W
公开号：
SG11202001387WA
申请日:
2018.08.30
申请国别(地区):
SG
年份:
2020
代理人:
摘要：
The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
